| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 49 | 2014 | 56 | 2.570 |
Why?
|
| Factor VIII | 23 | 2014 | 31 | 1.170 |
Why?
|
| HIV Seropositivity | 17 | 1995 | 82 | 0.510 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2015 | 12 | 0.490 |
Why?
|
| Acquired Immunodeficiency Syndrome | 11 | 1996 | 138 | 0.370 |
Why?
|
| Blood Coagulation Factors | 4 | 1996 | 13 | 0.340 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 40 | 0.300 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 55 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 194 | 0.280 |
Why?
|
| Leukocyte Count | 9 | 2015 | 97 | 0.240 |
Why?
|
| HIV | 6 | 1998 | 68 | 0.230 |
Why?
|
| Isoantibodies | 2 | 1996 | 33 | 0.230 |
Why?
|
| Hepatitis C | 6 | 1995 | 143 | 0.210 |
Why?
|
| HIV-1 | 8 | 1999 | 692 | 0.210 |
Why?
|
| Sexual Behavior | 2 | 1992 | 190 | 0.180 |
Why?
|
| HIV Infections | 10 | 1999 | 915 | 0.180 |
Why?
|
| Humans | 67 | 2015 | 59737 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 490 | 0.160 |
Why?
|
| Male | 36 | 2015 | 27952 | 0.160 |
Why?
|
| Genetic Therapy | 2 | 2005 | 735 | 0.150 |
Why?
|
| Transfusion Reaction | 4 | 1992 | 44 | 0.150 |
Why?
|
| Home Infusion Therapy | 2 | 2001 | 7 | 0.150 |
Why?
|
| Immunoglobulin G | 3 | 2014 | 446 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 2 | 1996 | 137 | 0.150 |
Why?
|
| Professional Staff Committees | 1 | 1997 | 5 | 0.140 |
Why?
|
| HIV Antibodies | 4 | 1994 | 133 | 0.140 |
Why?
|
| Malaria Vaccines | 1 | 1997 | 27 | 0.140 |
Why?
|
| Hemorrhage | 3 | 2001 | 259 | 0.140 |
Why?
|
| Vaccines, Synthetic | 1 | 1997 | 68 | 0.140 |
Why?
|
| Clinical Trials as Topic | 3 | 1997 | 440 | 0.130 |
Why?
|
| Factor IX | 5 | 2000 | 7 | 0.130 |
Why?
|
| Hemostasis | 1 | 1996 | 18 | 0.130 |
Why?
|
| Child, Preschool | 13 | 2001 | 1802 | 0.130 |
Why?
|
| Anterior Cruciate Ligament | 1 | 1995 | 15 | 0.120 |
Why?
|
| Leukapheresis | 1 | 2015 | 8 | 0.120 |
Why?
|
| Zidovudine | 2 | 1994 | 12 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 11 | 0.120 |
Why?
|
| Diverticulitis | 1 | 2015 | 28 | 0.120 |
Why?
|
| Cysts | 1 | 1995 | 40 | 0.120 |
Why?
|
| Adult | 29 | 2015 | 15771 | 0.120 |
Why?
|
| Autoantibodies | 2 | 2014 | 172 | 0.120 |
Why?
|
| Fluorescence Polarization Immunoassay | 1 | 2014 | 8 | 0.120 |
Why?
|
| Arthroplasty | 1 | 1994 | 4 | 0.120 |
Why?
|
| Child | 19 | 2001 | 4215 | 0.120 |
Why?
|
| Hepatitis Antibodies | 3 | 1992 | 6 | 0.120 |
Why?
|
| Sexual Partners | 3 | 1991 | 75 | 0.120 |
Why?
|
| Menisci, Tibial | 1 | 1994 | 24 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 68 | 0.120 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2014 | 90 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2011 | 19 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 1999 | 170 | 0.110 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1990 | 10 | 0.110 |
Why?
|
| Hemophilia B | 3 | 1996 | 5 | 0.110 |
Why?
|
| Immune Tolerance | 3 | 1993 | 172 | 0.100 |
Why?
|
| Immunophenotyping | 3 | 2009 | 184 | 0.100 |
Why?
|
| Comprehensive Health Care | 1 | 1993 | 17 | 0.100 |
Why?
|
| Adolescent | 16 | 2014 | 5866 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1994 | 245 | 0.100 |
Why?
|
| Knee Joint | 3 | 1995 | 286 | 0.100 |
Why?
|
| Repressor Proteins | 2 | 2011 | 334 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 15 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 13 | 0.090 |
Why?
|
| Hypersensitivity, Delayed | 3 | 1987 | 19 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 5147 | 0.090 |
Why?
|
| Growth Disorders | 1 | 1990 | 28 | 0.090 |
Why?
|
| Antigens | 2 | 1996 | 146 | 0.080 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2009 | 5 | 0.080 |
Why?
|
| Basophils | 1 | 2009 | 14 | 0.080 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 5 | 0.080 |
Why?
|
| Family Planning Services | 1 | 1988 | 22 | 0.080 |
Why?
|
| Antibodies | 1 | 1989 | 179 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 1995 | 1217 | 0.070 |
Why?
|
| Immune System | 1 | 1989 | 129 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2008 | 215 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 1992 | 446 | 0.070 |
Why?
|
| Aged | 11 | 2008 | 13510 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 3 | 1992 | 837 | 0.070 |
Why?
|
| Middle Aged | 16 | 2011 | 16449 | 0.060 |
Why?
|
| Infant | 7 | 2001 | 1496 | 0.060 |
Why?
|
| Hemarthrosis | 1 | 1985 | 3 | 0.060 |
Why?
|
| Antibody Formation | 3 | 2000 | 108 | 0.060 |
Why?
|
| Joint Diseases | 1 | 1985 | 18 | 0.060 |
Why?
|
| HIV Seronegativity | 2 | 1994 | 18 | 0.060 |
Why?
|
| Genes, nef | 2 | 1995 | 6 | 0.060 |
Why?
|
| Recombinant Proteins | 6 | 2000 | 691 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 5 | 1999 | 499 | 0.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 4 | 1991 | 109 | 0.050 |
Why?
|
| Risk Factors | 6 | 2001 | 5011 | 0.050 |
Why?
|
| Age Factors | 1 | 2005 | 1511 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 3 | 1991 | 130 | 0.040 |
Why?
|
| Pregnancy | 3 | 2015 | 2226 | 0.040 |
Why?
|
| Antibodies, Viral | 4 | 1987 | 293 | 0.040 |
Why?
|
| Female | 11 | 2015 | 30925 | 0.040 |
Why?
|
| HIV Long-Term Survivors | 1 | 1999 | 8 | 0.040 |
Why?
|
| Prospective Studies | 7 | 1996 | 3090 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 1994 | 2354 | 0.040 |
Why?
|
| Cohort Studies | 5 | 2001 | 2387 | 0.040 |
Why?
|
| Wounds, Gunshot | 1 | 1979 | 53 | 0.040 |
Why?
|
| Gene Products, gag | 3 | 1997 | 63 | 0.040 |
Why?
|
| Time Factors | 3 | 2014 | 3629 | 0.040 |
Why?
|
| DNA, Viral | 3 | 1995 | 223 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2005 | 1935 | 0.040 |
Why?
|
| Hypohidrosis | 1 | 1998 | 3 | 0.040 |
Why?
|
| Lymphoma, T-Cell | 1 | 1998 | 23 | 0.040 |
Why?
|
| Alopecia | 1 | 1998 | 25 | 0.040 |
Why?
|
| Sweat Gland Neoplasms | 1 | 1998 | 20 | 0.040 |
Why?
|
| Pruritus | 1 | 1998 | 29 | 0.040 |
Why?
|
| Sjogren's Syndrome | 1 | 1998 | 24 | 0.040 |
Why?
|
| Fractures, Bone | 1 | 1979 | 136 | 0.040 |
Why?
|
| Semen | 1 | 1998 | 42 | 0.040 |
Why?
|
| Leukocytes | 1 | 1998 | 97 | 0.040 |
Why?
|
| Blood Transfusion | 4 | 1992 | 150 | 0.030 |
Why?
|
| T-Lymphocytes | 3 | 1999 | 987 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1996 | 7 | 0.030 |
Why?
|
| Desensitization, Immunologic | 1 | 1996 | 9 | 0.030 |
Why?
|
| Contraindications | 1 | 1996 | 47 | 0.030 |
Why?
|
| Global Health | 2 | 1995 | 168 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 51 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2005 | 5334 | 0.030 |
Why?
|
| Immunization | 1 | 1996 | 128 | 0.030 |
Why?
|
| Anaphylaxis | 1 | 1996 | 40 | 0.030 |
Why?
|
| Martial Arts | 1 | 1995 | 1 | 0.030 |
Why?
|
| Patella | 1 | 1995 | 13 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 1994 | 621 | 0.030 |
Why?
|
| Factor VII | 2 | 1992 | 3 | 0.030 |
Why?
|
| Species Specificity | 1 | 1996 | 329 | 0.030 |
Why?
|
| Tendons | 1 | 1995 | 24 | 0.030 |
Why?
|
| Bone Transplantation | 1 | 1995 | 23 | 0.030 |
Why?
|
| Live Birth | 1 | 2015 | 20 | 0.030 |
Why?
|
| Pulmonary Ventilation | 1 | 2015 | 37 | 0.030 |
Why?
|
| Bone Resorption | 1 | 1995 | 41 | 0.030 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 1995 | 30 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1995 | 120 | 0.030 |
Why?
|
| Swine | 1 | 1996 | 360 | 0.030 |
Why?
|
| Reference Values | 2 | 1992 | 330 | 0.030 |
Why?
|
| HIV Antigens | 2 | 1991 | 18 | 0.030 |
Why?
|
| HIV Core Protein p24 | 2 | 1991 | 17 | 0.030 |
Why?
|
| Tibia | 1 | 1995 | 70 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 1994 | 22 | 0.030 |
Why?
|
| Knee Injuries | 1 | 1995 | 47 | 0.030 |
Why?
|
| Arthroscopy | 1 | 1994 | 25 | 0.030 |
Why?
|
| Patient Selection | 1 | 1997 | 467 | 0.030 |
Why?
|
| von Willebrand Diseases | 2 | 1992 | 4 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 116 | 0.030 |
Why?
|
| Osteotomy | 1 | 1994 | 14 | 0.030 |
Why?
|
| Blotting, Western | 2 | 1992 | 590 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2015 | 97 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1994 | 133 | 0.030 |
Why?
|
| Hospitalization | 1 | 2001 | 1300 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1995 | 293 | 0.030 |
Why?
|
| Radiography | 1 | 1995 | 519 | 0.030 |
Why?
|
| Lymphocyte Activation | 3 | 1999 | 743 | 0.030 |
Why?
|
| Hepatitis B | 3 | 1992 | 29 | 0.030 |
Why?
|
| Blood Donors | 2 | 1990 | 22 | 0.030 |
Why?
|
| Drug Contamination | 2 | 1990 | 15 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 1998 | 398 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 105 | 0.030 |
Why?
|
| Gene Products, nef | 1 | 1992 | 13 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1992 | 36 | 0.030 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 1992 | 24 | 0.030 |
Why?
|
| CD4 Antigens | 2 | 1991 | 148 | 0.020 |
Why?
|
| Prevalence | 3 | 1992 | 1259 | 0.020 |
Why?
|
| Factor VII Deficiency | 1 | 1992 | 1 | 0.020 |
Why?
|
| Factor VIIIa | 1 | 1992 | 1 | 0.020 |
Why?
|
| Factor IXa | 1 | 1992 | 1 | 0.020 |
Why?
|
| Factor X | 1 | 1992 | 2 | 0.020 |
Why?
|
| Prothrombin | 1 | 1992 | 3 | 0.020 |
Why?
|
| Factor VIIa | 1 | 1992 | 3 | 0.020 |
Why?
|
| Skin Tests | 3 | 1986 | 20 | 0.020 |
Why?
|
| Prenatal Diagnosis | 2 | 1992 | 39 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 1992 | 38 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1038 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1991 | 3 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 33 | 0.020 |
Why?
|
| Placebos | 1 | 1991 | 68 | 0.020 |
Why?
|
| Herpesviridae Infections | 3 | 1986 | 25 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 63 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 74 | 0.020 |
Why?
|
| HTLV-I Antibodies | 1 | 1990 | 2 | 0.020 |
Why?
|
| Virus Diseases | 1 | 1992 | 114 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 12 | 0.020 |
Why?
|
| Growth | 1 | 1990 | 22 | 0.020 |
Why?
|
| Pedigree | 1 | 1991 | 183 | 0.020 |
Why?
|
| Virus Replication | 3 | 1999 | 305 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2011 | 133 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 1987 | 208 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1613 | 0.020 |
Why?
|
| Risk | 2 | 1988 | 368 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 1991 | 181 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1991 | 256 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1991 | 167 | 0.020 |
Why?
|
| Immunity, Cellular | 2 | 1989 | 171 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1315 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1989 | 51 | 0.020 |
Why?
|
| Half-Life | 1 | 1989 | 75 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2009 | 38 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 3 | 1986 | 178 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2009 | 63 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 1989 | 86 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 152 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1991 | 277 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1989 | 137 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 2 | 1999 | 90 | 0.020 |
Why?
|
| CD8 Antigens | 3 | 1994 | 53 | 0.020 |
Why?
|
| Deltaretrovirus | 2 | 1986 | 2 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 234 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1989 | 135 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1988 | 217 | 0.020 |
Why?
|
| New England | 1 | 1988 | 268 | 0.020 |
Why?
|
| Dermatitis, Contact | 1 | 1987 | 12 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 645 | 0.020 |
Why?
|
| Cytomegalovirus | 2 | 1986 | 90 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 1988 | 92 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 1988 | 742 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 632 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 608 | 0.020 |
Why?
|
| Hepatitis B Antigens | 1 | 1985 | 5 | 0.020 |
Why?
|
| Animals | 2 | 1996 | 19705 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 4290 | 0.010 |
Why?
|
| Motion | 1 | 1985 | 56 | 0.010 |
Why?
|
| Long-Term Care | 1 | 1985 | 177 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1987 | 1192 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 3 | 1992 | 66 | 0.010 |
Why?
|
| World Health Organization | 2 | 1995 | 30 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1998 | 1955 | 0.010 |
Why?
|
| Virus Cultivation | 2 | 1994 | 18 | 0.010 |
Why?
|
| Developing Countries | 2 | 1995 | 86 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 1982 | 5 | 0.010 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 1982 | 18 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 1982 | 98 | 0.010 |
Why?
|
| Antigens, Viral | 3 | 1987 | 130 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 1988 | 2520 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1991 | 29 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 1999 | 37 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2001 | 197 | 0.010 |
Why?
|
| United States | 2 | 1990 | 7448 | 0.010 |
Why?
|
| Neutrophils | 1 | 1982 | 365 | 0.010 |
Why?
|
| Chemokines | 1 | 1999 | 93 | 0.010 |
Why?
|
| Extremities | 1 | 1979 | 44 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1999 | 186 | 0.010 |
Why?
|
| Viral Load | 1 | 1999 | 220 | 0.010 |
Why?
|
| Disease Reservoirs | 1 | 1998 | 9 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 1985 | 688 | 0.010 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 1982 | 397 | 0.010 |
Why?
|
| HIV Protease Inhibitors | 1 | 1998 | 105 | 0.010 |
Why?
|
| Phylogeny | 1 | 1998 | 337 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1998 | 259 | 0.010 |
Why?
|
| HIV Protease | 1 | 1998 | 120 | 0.010 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1996 | 68 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1998 | 357 | 0.010 |
Why?
|
| Mice | 1 | 1989 | 10316 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 1995 | 12 | 0.010 |
Why?
|
| Developed Countries | 1 | 1995 | 16 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 1556 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1994 | 26 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1994 | 48 | 0.010 |
Why?
|
| Viremia | 1 | 1994 | 44 | 0.010 |
Why?
|
| Primary Prevention | 1 | 1995 | 134 | 0.010 |
Why?
|
| Genes, gag | 1 | 1993 | 11 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1993 | 32 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1993 | 18 | 0.010 |
Why?
|
| Safety | 1 | 1993 | 141 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 1302 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 1992 | 14 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 1992 | 15 | 0.010 |
Why?
|
| Fetal Diseases | 1 | 1992 | 21 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1991 | 28 | 0.010 |
Why?
|
| International Cooperation | 1 | 1992 | 84 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 1991 | 35 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 1991 | 31 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1991 | 75 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1992 | 126 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1991 | 147 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1991 | 61 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1990 | 47 | 0.010 |
Why?
|
| Hemostasis, Surgical | 1 | 1990 | 17 | 0.010 |
Why?
|
| HTLV-I Infections | 1 | 1990 | 3 | 0.010 |
Why?
|
| France | 1 | 1990 | 14 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1990 | 59 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 1990 | 12 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1990 | 38 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1990 | 35 | 0.010 |
Why?
|
| Disease Progression | 1 | 1995 | 1126 | 0.010 |
Why?
|
| Health Education | 1 | 1992 | 184 | 0.010 |
Why?
|
| Phenotype | 1 | 1994 | 1142 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1992 | 401 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1991 | 343 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1991 | 164 | 0.010 |
Why?
|
| Polymers | 1 | 1993 | 317 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1989 | 98 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1989 | 98 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1992 | 330 | 0.000 |
Why?
|
| Freeze Drying | 1 | 1988 | 14 | 0.000 |
Why?
|
| Self Administration | 1 | 1988 | 48 | 0.000 |
Why?
|
| Incidence | 1 | 1992 | 1245 | 0.000 |
Why?
|
| Blood Cells | 1 | 1987 | 17 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1989 | 218 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1991 | 922 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1991 | 1289 | 0.000 |
Why?
|
| Neoplasms | 1 | 1996 | 1238 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1989 | 551 | 0.000 |
Why?
|
| Hepatitis delta Antigens | 1 | 1985 | 2 | 0.000 |
Why?
|
| Homosexuality | 1 | 1985 | 6 | 0.000 |
Why?
|
| Afghanistan | 1 | 1985 | 11 | 0.000 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1985 | 17 | 0.000 |
Why?
|
| Retroviridae Infections | 1 | 1985 | 12 | 0.000 |
Why?
|
| Epidemiologic Methods | 1 | 1985 | 65 | 0.000 |
Why?
|
| Fibrinogen | 1 | 1985 | 32 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1984 | 184 | 0.000 |
Why?
|
| Hepatitis B virus | 1 | 1984 | 13 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1987 | 2095 | 0.000 |
Why?
|
| Prisoners | 1 | 1985 | 151 | 0.000 |
Why?
|
| Genetic Vectors | 1 | 1989 | 809 | 0.000 |
Why?
|
| Phorbol Esters | 1 | 1982 | 4 | 0.000 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 1982 | 5 | 0.000 |
Why?
|
| Peroxides | 1 | 1982 | 11 | 0.000 |
Why?
|
| Neuraminidase | 1 | 1982 | 43 | 0.000 |
Why?
|
| Carrier Proteins | 1 | 1982 | 697 | 0.000 |
Why?
|